JP2023518293A5 - - Google Patents
Info
- Publication number
- JP2023518293A5 JP2023518293A5 JP2022556560A JP2022556560A JP2023518293A5 JP 2023518293 A5 JP2023518293 A5 JP 2023518293A5 JP 2022556560 A JP2022556560 A JP 2022556560A JP 2022556560 A JP2022556560 A JP 2022556560A JP 2023518293 A5 JP2023518293 A5 JP 2023518293A5
- Authority
- JP
- Japan
- Prior art keywords
- recombinant polypeptide
- human
- nucleic acid
- acid molecule
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062992806P | 2020-03-20 | 2020-03-20 | |
| US62/992,806 | 2020-03-20 | ||
| US202163137022P | 2021-01-13 | 2021-01-13 | |
| US63/137,022 | 2021-01-13 | ||
| PCT/US2021/023337 WO2021189008A1 (en) | 2020-03-20 | 2021-03-19 | Novel recombinant cell surface markers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023518293A JP2023518293A (ja) | 2023-04-28 |
| JP2023518293A5 true JP2023518293A5 (cg-RX-API-DMAC7.html) | 2024-03-28 |
Family
ID=75478279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022556560A Pending JP2023518293A (ja) | 2020-03-20 | 2021-03-19 | 新規の組換え細胞表面マーカー |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12054531B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4121447A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023518293A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220156041A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115605503A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021239360A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022018491A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3159639A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL296511A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022011673A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021189008A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| WO2024020429A1 (en) * | 2022-07-22 | 2024-01-25 | Lyell Immunopharma, Inc. | Immune cell therapy |
| WO2024182539A1 (en) | 2023-02-28 | 2024-09-06 | Lyell Immunopharma, Inc. | Methods of culturing reprogrammed cells |
| IL325764A (en) | 2023-07-13 | 2026-03-01 | Outpace Bio Inc | Designed interleukin-2 cytokine compositions and methods for use |
| WO2025059663A1 (en) | 2023-09-14 | 2025-03-20 | Outpace Bio, Inc. | Anti-exhaustion compositions and methods of use thereof |
| WO2026102456A1 (en) | 2024-11-11 | 2026-05-15 | Lyell Immunopharma, Inc. | Methods of treating cancer by administering bispecific cd19/cd20 car t cells |
| CN121538180A (zh) * | 2025-11-28 | 2026-02-17 | 中国医学科学院肿瘤医院 | 经修饰的单核细胞、其制备方法和应用 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL86278A (en) | 1988-05-04 | 2003-06-24 | Yeda Res & Dev | Endowing cells with antibody specificity using chimeric t cell receptor |
| US6790614B1 (en) | 1999-11-19 | 2004-09-14 | Novartis Ag | Selectable cell surface marker genes |
| JP5956342B2 (ja) | 2009-11-03 | 2016-07-27 | シティ・オブ・ホープCity of Hope | 形質導入T細胞選択のためのトランケート上皮増殖因子レセプタ(EGFRt) |
| EP2646469B1 (en) | 2010-12-01 | 2017-11-01 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Chimeric rabbit/human ror1 antibodies |
| EP2814846B1 (en) * | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| SG10201808811QA (en) | 2014-04-10 | 2018-11-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Method and compositions for cellular immunotherapy |
| WO2015161835A1 (de) * | 2014-04-20 | 2015-10-29 | New / Era / Mabs Gmbh | Biomoleküle freisetzende zelle und deren selektion mittels eines oberflächenproteins |
| WO2015164759A2 (en) * | 2014-04-25 | 2015-10-29 | Bluebird Bio, Inc. | Mnd promoter chimeric antigen receptors |
| EP3250602A1 (en) | 2015-01-26 | 2017-12-06 | Cellectis | T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm |
| SG10201913151TA (en) | 2015-09-09 | 2020-03-30 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Genetic engineering of macrophages for immunotherapy |
| MX2018004721A (es) | 2015-10-23 | 2018-07-06 | Eureka Therapeutics Inc | Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas. |
| CN106967684A (zh) | 2016-01-13 | 2017-07-21 | 北京马力喏生物科技有限公司 | 共表达抗EGFRvIII嵌合抗原受体和无功能EGFR受体的转基因淋巴细胞及其用途 |
| CN106967681B (zh) | 2016-01-13 | 2020-06-05 | 北京马力喏生物科技有限公司 | 治疗脑胶质母细胞瘤的治疗组合物 |
| CN107586342A (zh) | 2016-07-08 | 2018-01-16 | 生命序有限公司 | 重组免疫检查点受体及其应用 |
| CN107586341A (zh) | 2016-07-08 | 2018-01-16 | 生命序有限公司 | 重组免疫检查点受体及免疫检查点抑制分子的共表达及应用 |
| CN108342361B (zh) | 2017-01-25 | 2020-12-22 | 北京马力喏生物科技有限公司 | 治疗间质素阳性肿瘤的治疗组合物 |
| CN108342360A (zh) | 2017-01-25 | 2018-07-31 | 北京马力喏生物科技有限公司 | 共表达抗msln嵌合抗原受体和无功能egfr的转基因淋巴细胞及其用途 |
| WO2018200582A1 (en) | 2017-04-26 | 2018-11-01 | Eureka Therapeutics, Inc. | Chimeric antibody/t-cell receptor constructs and uses thereof |
| US11149073B2 (en) | 2017-04-28 | 2021-10-19 | Julius-Maximilians-Universität Würzburg | ROR1-specific chimeric antigen receptors (CAR) with humanized targeting domains |
| EP3692057B9 (en) | 2017-10-03 | 2023-10-04 | Precision BioSciences, Inc. | Modified epidermal growth factor receptor peptides for use in genetically-modified cells |
| WO2019072824A1 (en) | 2017-10-09 | 2019-04-18 | Cellectis | IMPROVED ANTI-CD123 CAR IN UNIVERSAL MODIFIED IMMUNE T LYMPHOCYTES |
| EP3723774A4 (en) | 2017-12-15 | 2021-09-08 | The Board of Trustees of the Leland Stanford Junior University | COMPOSITIONS AND METHODS OF INHIBITION OF T-CELL EXHAUSTATION |
| AU2019216269B2 (en) | 2018-01-30 | 2025-05-01 | Cellectis | Combination comprising allogeneic immune cells deficient for an antigen present on both T-cells and pathological cells and therapeutic antibody against said antigen |
| US10663465B2 (en) * | 2018-03-05 | 2020-05-26 | The Hong Kong University Of Science And Technology | Disruption of EGFR-SAR1 interaction for cancer treatment |
| CN110526983B (zh) | 2018-05-24 | 2022-02-11 | 北京马力喏生物科技有限公司 | 改良型抗cd19 car-t细胞 |
| CA3105816A1 (en) | 2018-07-10 | 2020-01-16 | Precigen, Inc. | Ror-1 specific chimeric antigen receptors and uses thereof |
| US20210322473A1 (en) | 2018-07-18 | 2021-10-21 | The General Hospital Corporation | Modified t cells and methods of their use |
| KR20210074274A (ko) | 2018-08-06 | 2021-06-21 | 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 | 합텐 표지된 세포로의 키메라 항원 수용체 t 세포의 자극을 위한 방법 및 조성물 |
| CN112996819B (zh) | 2018-08-16 | 2025-11-04 | 纪念斯隆-凯特琳癌症中心 | 细胞分选系统及使用方法 |
| CN112930186A (zh) | 2018-08-16 | 2021-06-08 | 纪念斯隆-凯特琳癌症中心 | 基于亮氨酸拉链的组合物和使用方法 |
| EP3856769A4 (en) | 2018-09-28 | 2022-08-17 | Memorial Sloan Kettering Cancer Center | IMMUNOREACTIVE CELLS EXPRESSING DOMINANT NEGATIVE FAS AND USES THEREOF |
| KR20210072797A (ko) | 2018-10-05 | 2021-06-17 | 세인트 안나 킨더크렙스포르슝 | 키메라 항원 수용체(car) 그룹 |
| CN111088231A (zh) | 2018-10-24 | 2020-05-01 | 艾生命序公司 | Pd-l1抗体分泌的抗间皮素car-t细胞肿瘤免疫治疗 |
| EP4578507A3 (en) | 2018-11-01 | 2025-11-12 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for t cell engineering |
| JP7352307B2 (ja) | 2019-03-15 | 2023-09-28 | 阿思科力(蘇州)生物科技有限公司 | 自殺遺伝子を持つrobo1 car-nk細胞、その製造方法及び使用 |
| WO2021222479A1 (en) | 2020-04-28 | 2021-11-04 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| MX2022014203A (es) | 2020-05-12 | 2023-02-22 | Lyell Immunopharma Inc | Espaciadores de receptores de antígenos quiméricos (car). |
| EP4298230A1 (en) | 2021-02-25 | 2024-01-03 | Lyell Immunopharma, Inc. | Codon-optimized nucleotide sequences encoding an ap-1 transcription factor |
| AU2022226660A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
-
2021
- 2021-03-19 EP EP21718393.8A patent/EP4121447A1/en active Pending
- 2021-03-19 AU AU2021239360A patent/AU2021239360A1/en active Pending
- 2021-03-19 JP JP2022556560A patent/JP2023518293A/ja active Pending
- 2021-03-19 CA CA3159639A patent/CA3159639A1/en active Pending
- 2021-03-19 IL IL296511A patent/IL296511A/en unknown
- 2021-03-19 MX MX2022011673A patent/MX2022011673A/es unknown
- 2021-03-19 CN CN202180031270.7A patent/CN115605503A/zh active Pending
- 2021-03-19 US US17/207,523 patent/US12054531B2/en active Active
- 2021-03-19 WO PCT/US2021/023337 patent/WO2021189008A1/en not_active Ceased
- 2021-03-19 KR KR1020227035983A patent/KR20220156041A/ko active Pending
- 2021-03-19 BR BR112022018491A patent/BR112022018491A2/pt unknown
-
2024
- 2024-06-21 US US18/750,174 patent/US20240409610A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2752248T3 (es) | Heterodímero proteínico y uso del mismo | |
| US10730943B2 (en) | Means and methods for treating HBV infection and associated conditions | |
| JP2024500847A5 (cg-RX-API-DMAC7.html) | ||
| US11987609B2 (en) | Proteinaceous heterodimer and use thereof | |
| AU2021418636A1 (en) | Cd7-targeted engineered immune cell, chimeric antigen receptor, cd7 blocking molecule and use thereof | |
| WO2019154349A1 (zh) | 抗pd-1/抗vegf天然抗体结构样异源二聚体形式双特异抗体及其制备 | |
| RU2018147423A (ru) | Анти-PD-L1 и IL-2 цитокины | |
| KR20190129896A (ko) | Tgf-β-수용체 엑토도메인 융합 분자 및 그의 용도 | |
| CN109734800B (zh) | 一种裂谷热病毒人源单克隆抗体及其应用 | |
| RS66502B1 (sr) | Bispecifični ili-kapijski himerni antigenski receptor koji reaguje na cd19 i cd20 | |
| JP2017527310A5 (cg-RX-API-DMAC7.html) | ||
| CN111699201A (zh) | 抗pd-1/抗her2天然抗体结构的异源二聚双特异性抗体及其制备方法 | |
| CN102633883A (zh) | 一种能与egfr、her2、vegf高效结合的融合蛋白、其编码序列及用途 | |
| JP2021531834A5 (cg-RX-API-DMAC7.html) | ||
| CN111892661A (zh) | 一种嵌合抗原受体及其在制备治疗肿瘤的产品中的应用 | |
| CN104974262B (zh) | 重组双功能融合蛋白及其制法和用途 | |
| WO2025067115A1 (zh) | 核酸、载体、转基因免疫细胞及其应用 | |
| WO2020192648A1 (en) | Proteinaceous heterodimer and use thereof | |
| WO2021143695A1 (zh) | 一种抗肿瘤融合蛋白及其制法和应用 | |
| CN111499723A (zh) | 一种嵌合抗原受体及其应用 | |
| CN118726265A (zh) | 自分泌多特异性纳米抗体的工程化免疫细胞 | |
| CN119731199A (zh) | 工程化的白细胞介素-2受体β降低结合的激动剂 | |
| WO2019129142A1 (zh) | 自分泌CD40抗体且靶向ErbB受体家族的CAR-T细胞及其用途 | |
| CA3228311A1 (en) | Bispecific recombinant protein and use thereof | |
| CN110396131A (zh) | 一种ErbB2单链抗体、靶向人ErbB2的嵌合抗原受体、重组载体、重组细胞和应用 |